Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

The Jury Is Still Out on the Benefits and Harms of Methylphenidate for Children and Adolescents With Attention-Deficit/Hyperactivity Disorder

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{270ad55664a14594abb1b093d1db3803,
title = "The Jury Is Still Out on the Benefits and Harms of Methylphenidate for Children and Adolescents With Attention-Deficit/Hyperactivity Disorder",
abstract = "Much remains unclear about the benefits and harms of methylphenidate for children and adolescents with attention-deficit/hyperactivity disorder (ADHD). Between 2012 and 2018, we conducted two Cochrane systematic reviews on methylphenidate for ADHD. This article explores the main findings in relation to evidence-based practice and our current understanding of ADHD.",
author = "Storeb{\o}, {Ole Jakob} and Erlend Faltinsen and Morris Zwi and Erik Simonsen and Christian Gluud",
note = "{\circledC} 2018 American Society for Clinical Pharmacology and Therapeutics.",
year = "2018",
month = "7",
day = "13",
doi = "10.1002/cpt.1149",
language = "English",
volume = "104",
pages = "606--609",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "4",

}

RIS

TY - JOUR

T1 - The Jury Is Still Out on the Benefits and Harms of Methylphenidate for Children and Adolescents With Attention-Deficit/Hyperactivity Disorder

AU - Storebø, Ole Jakob

AU - Faltinsen, Erlend

AU - Zwi, Morris

AU - Simonsen, Erik

AU - Gluud, Christian

N1 - © 2018 American Society for Clinical Pharmacology and Therapeutics.

PY - 2018/7/13

Y1 - 2018/7/13

N2 - Much remains unclear about the benefits and harms of methylphenidate for children and adolescents with attention-deficit/hyperactivity disorder (ADHD). Between 2012 and 2018, we conducted two Cochrane systematic reviews on methylphenidate for ADHD. This article explores the main findings in relation to evidence-based practice and our current understanding of ADHD.

AB - Much remains unclear about the benefits and harms of methylphenidate for children and adolescents with attention-deficit/hyperactivity disorder (ADHD). Between 2012 and 2018, we conducted two Cochrane systematic reviews on methylphenidate for ADHD. This article explores the main findings in relation to evidence-based practice and our current understanding of ADHD.

U2 - 10.1002/cpt.1149

DO - 10.1002/cpt.1149

M3 - Journal article

VL - 104

SP - 606

EP - 609

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 4

ER -

ID: 54833158